Review Article

Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?

Table 1

Selected publications surveying the clinical and preclinical evidence for immunomodulatory effects of RFA and cryoablation.

ModalityCell typeImmune componentSpeciesRef.

RFA
Potential tumor suppression
VX2 tumor-specific T-cells; T-cell infiltrationRabbit[44]
HCCDC activation; serum TNF-, IL-1Human[31]
HCCTumor-specific CD4+ and CD8+ responseHuman[90]
HCC HSP70 in tumor cell surface and cytoplasmHuman[91]
Primary and metastatic liver, kidney, and lung cancer HSP70Human[41]
Primary and metastatic liver tumors memory T-cell trafficking, T-cell proliferation in metastatic cancer patientsHuman[92]
HCC tumor-specific CD8+, correlating with progression-free survival after ablationHuman[43]
Primary and metastatic lung tumors ; serum IL-8, IL-10, C3, C4, and CRPHuman[32]
Colon and kidney tumors and melanoma antigen-specific antibodies, CD4+ and CD8+ T-cellsHuman[46]
HCC NK cell stimulationHuman[93]
Primary and metastatic colon, liver, kidney, and lung tumors, melanoma, and sarcoma serum IL-6, IL-10; serum TNF-, IL-1, and IL-2Human[33]
MelanomaReduced tumor recurrence when combined with DC tumoral vaccineMouse[86]
MelanomaDC activation; immunization against rechallenge with anti-CTLA-4 therapyMouse[9, 94]
Urothelial cancerTumor-specific T-cell activation, immunization against rechallengeMouse[37]
Hepatocytes IL-6Rat[34]
Hepatocytes apoptosis, HSP70 in transition zonePig[95]
Potential tumor stimulation
Hepatocytes intracellular HSP70 expression in tumor cells near blood vesselsRat[96]
Hepatocytes (MDR2 knockout) tumor development, survival; effect diminished with c-Met inhibitorMouse[3]
Hepatocytes breast cancer xenograft growth; effect diminished with c-Met/VEGF inhibitorsRat[47]
Colorectal hypoxia, HIF-1, and HIF-2 in transition zone leading to tumor growthMouse/rat[49]
HCC HIF-1, VEGF, and angiogenesisMouse[51]
Hepatocytes breast cancer xenograft growth; effect diminished with anti-IL-6 siRNAMouse/rat[54]
Cryoablation
Potential tumor suppression
ProstateRemission of metastases following prostate cryoablationHuman[55, 58]
SarcomaRegression of remote tumor; immunization against rechallengeRat[57]
BreastTumor-specific T-cell response; immunization against rechallengeMouse[61]
MelanomaCombination with TLR9 stimulation reduces local and remote tumorsMouse[83]
MelanomaDC activation; immunization against rechallenge with anti-CTLA-4 therapyMouse[9]
HCC IL-6, CRP, and IL-10; TNF- and Th1/Th2 associated with remote tumor regressionHuman[97]
Prostate TNF-, IFN-, and Th1/Th2; tumor-specific T-cell responseHuman[98]
Lung metastasesCombination with GM-CSF caused tumor-specific T-cell response and anti-tumor antibodiesHuman[88]
Lung tumor, melanomaCombination with DC therapy tumor-specific CD8+ T-cell response, survivalMouse[82]
ColonDC + Bacillus Calmette-Guérin cell wall skeleton caused tumor-specific CD8+ T-cell response and local and remote tumor regressionMouse[99]
Potential tumor suppression
Fibrosarcoma mortality from metastases compared to surgical excision; excision of cryoablated tumor reduced rate of metastasisRat[64]
Fibrosarcoma growth of pulmonary metastases after cryoablation of flank tumorRat[65]
BreastLow freeze rate can , remote metastases, and survivalMouse[68]